- July 27, 2022
- 12:05 PM - 1:00 PM ET
Tell us what you think about the town halls
The U.S. Food and Drug Administration (FDA) hosts regular virtual Town Halls for SARS-CoV-2 test developers. The purpose of these Town Halls is to help answer technical questions about the development and validation of tests for SARS-CoV-2. Registration is not necessary.
There will be an opportunity to ask questions live during the Town Halls, but questions may also be submitted in advance by emailing CDRHWebinars@fda.hhs.gov.
- Please submit questions by Monday 12 p.m. ET before the Wednesday virtual Town Hall.
- In the subject line of the email, state "Question for the COVID-19 Test Virtual Town Hall"
Save the Date:
The FDA will hold a virtual Town Hall for test developers from 12:05 p.m.-1 p.m. ET on:
- July 27: Town Hall #89
- August 24: Town Hall #90
Add July and August Dates to My Calendar
Outlook users: Click link, select Open, then click Save & Close
The FDA plays a critical role in protecting the United States from threats such as emerging infectious diseases, including Coronavirus Disease 2019 (COVID-19). The FDA is committed to providing timely guidance to support response efforts to this pandemic.
The guidance "Policy for Coronavirus Disease-2019 Tests During the Public Health Emergency (Revised)" includes policies specific to this public health emergency.
The recording and transcript from the previous town halls are available for viewing.
Registration is not necessary.
Time: 12:05 p.m. - 1 p.m. ET
To ensure you are connected, please join 15 minutes before the start of the virtual Town Hall.
Please click the link below to join the webinar:
Please note: Participants who join the virtual Town Hall using the Zoom webinar link above should use computer audio (listen through computer speakers and speak through computer microphone/headset to ask a question).
The dial-in information provided below is for participants who will be joining the virtual Town Hall by phone only.
U.S. Callers Dial: 833-568-8864
Webinar ID: 161 026 4546
Following the webinar, a transcript, recording, and slides will be posted below.